RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

Recursion Pharmaceuticals (RXRX) experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs ...